Form 4: DexCom Director Nicholas Augustinos Transfers Shares to Trust

DexCom director Nicholas Augustinos transferred 5,046 shares of common stock into a revocable trust.

Summary

• Director Nicholas Augustinos transferred 5,046 shares of DexCom common stock from direct ownership to the Kirschner/Augustinos Revocable Trust.
• The transaction occurred on May 8, 2026, at a price of $0, representing a transfer of beneficial ownership rather than a market sale.
• Following the transaction, the director holds 38,457 shares indirectly through the trust and zero shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative transfer of shares rather than a change in the director's investment position.

Positives

• The transaction reflects a consolidation of holdings into a trust structure, which is a standard estate planning practice.
• There was no divestment of equity; the director maintains beneficial ownership of the shares.

Negatives

• None identified; this is a routine administrative filing regarding ownership structure.

Risks

• None identified; this filing does not impact the company's operational or financial risk profile.

Future Outlook

Not applicable; this is a disclosure of a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that routine insider ownership changes, such as transfers to trusts, are common among corporate directors and generally do not signal changes in management sentiment or company performance.

Comparison to Industry Standards

• The filing adheres to standard SEC Section 16(a) reporting requirements for directors.
• The use of a revocable trust for estate planning is consistent with standard practices for high-net-worth corporate executives.

Related Party Transactions

• The transaction involves the Kirschner/Augustinos Revocable Trust, of which the reporting person is a trustee.

Stakeholder Impact

• No material impact on shareholders, employees, or other stakeholders.

Next Steps

• No further actions required by the company or the reporting person regarding this specific transaction.

Key Dates

Keywords

DexCom, DXCM, Form 4, Insider Trading, Beneficial Ownership, Nicholas Augustinos